Non-small cell lung cancer (NSCLC)

Lung cancer is the leading malignant cause of death in 93 countries, accounting for a fifth of the total global burden of disability-adjusted life years from cancer.1

Non-small cell lung cancer comprises 85% of all lung cancers.2

Molecular testing, like mutation analysis of the epidermal growth factor gene (EGFR), is crucial for first-line treatment. Targeted oncological therapy, for instance, blocks the growth and spread of cancer cells while limiting damage to healthy cells.

Roche assays support diagnostic laboratories in identifying EGFR in NSCLC patients.

References:

  1. Soerjomataram I, Lortet-Tieulent J, Parkin DM et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380(9856):1840-1850.
  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.